A carregar...
Projeto de investigação
Sem título
Financiador
Autores
Publicações
DNA damage independent inhibition of NF-κB transcription by anthracyclines
Publication . Pedroso, Dora; Chora, Ângelo Ferreira; Kyriakou, Eleni; Pejanovic, Nadja; Colaço, Henrique; Gozzelino, Raffaella; Barros, André; Willmann, Katharina; Velho, Tiago R.; Moita, Catarina; Santos, Isa; Pereira, Pedro; Carvalho, Silvia; Martins, Filipa Batalha; Ferreira, João; de Almeida, Sérgio F.; Benes, Vladimir; Anrather, Josef; Weis, Sebastian; Soares, Miguel P; Geerlof, Arie; Neefjes, Jacques; Sattler, Michael; Messias, Ana C; Neves-Costa, Ana; Moita, Luis
Anthracyclines are among the most used and effective anticancer drugs. Their activity has been attributed to DNA double-strand breaks resulting from topoisomerase II poisoning and to eviction of histones from select sites in the genome. Here, we show that the extensively used anthracyclines Doxorubicin, Daunorubicin, and Epirubicin decrease the transcription of nuclear factor kappa B (NF-κB)-dependent gene targets, but not interferon-responsive genes in primary mouse (Mus musculus) macrophages. Using an NMR-based structural approach, we demonstrate that anthracyclines disturb the complexes formed between the NF-κB subunit RelA and its DNA-binding sites. The anthracycline variants Aclarubicin, Doxorubicinone, and the newly developed Dimethyl-doxorubicin, which share anticancer properties with the other anthracyclines but do not induce DNA damage, also suppressed inflammation, thus uncoupling DNA damage from the effects on inflammation. These findings have implications for anticancer therapy and for the development of novel anti-inflammatory drugs with limited side effects for life-threatening conditions such as sepsis.
Unidades organizacionais
Descrição
Palavras-chave
Contribuidores
Financiadores
Entidade financiadora
Fundação para a Ciência e a Tecnologia
Programa de financiamento
3599-PPCDT
Número da atribuição
PTDC/BIM-MEC/4665/2014